$21.1M capital deployed

32% primary ownership

Jun '11 initial capital deployed

return to top

Why NovaSom?

Headquartered in Glen Burnie, MD, NovaSom is a leader in Obstructive Sleep Apnea (“OSA”) home testing, with the AccuSom® home sleep test, the only comprehensively supported home sleep test that provides continuous patient support and next-day test results and interpretation for health care professionals.

The U.S. Food and Drug Administration (“FDA”)-cleared AccuSom is as accurate as sleep lab testing and significantly more convenient and comfortable for patients. Patients are able to test around their own schedule and can sleep in their own bed, which helps eliminate “first night” effect and improves data collection.

The OSA diagnostic market in the U.S. is estimated to be approximately $4 billion and is growing more than 15% annually. Only 3 million sufferers in the U.S. have been diagnosed to date, out of an estimated 40 million moderate to severe OSA sufferers.

AccuSom is currently covered for more than 150 million commercially insured U.S. lives. NovaSom is accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center & Telehealth Provider and is classified by the Centers for Medicare & Medicaid Services as an Independent Diagnostic Testing Facility.

(Updated as of 03/31/15)

By giving patients the option to conduct tests for OSA in their homes, we hope to identify and treat more of the millions of undiagnosed sufferers. Safeguard’s financial and operational support have augmented our traction to date, expanded our market penetration and ultimately impacted our patients’ quality of life.

– John Spitznagel, CEO, NovaSom